View Post

Immunotherapy combination effective for patients with rare neuroendocrine cancer

In Clinical Trials by Barbara Jacoby

Source: SWOG From: eurekalert.org A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to new research results presented at the American Association for Cancer Research Annual Meeting 2019, held March 29-April 3 in Atlanta. Results from the SWOG Cancer Research Network trial known as DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, show …

View Post

CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: apnews.com CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The data from all 928 enrolled patients were provided to the …

View Post

Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

In Clinical Trials by Barbara Jacoby

Provider: Business Wire From: apnews.com Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “ Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients” at the American Association for Cancer Research (AACR) Annual Meeting underway in Atlanta. The discussion …

View Post

NCCN: Updated Guidelines Reflect Advances, ‘Immunotherapy Era’ for Breast Cancer

In In The News by Barbara Jacoby

By: Bryant Furlow From: cancernetwork.com Updates to the National Comprehensive Cancer Network (NCCN) Guidelines® on breast cancer reflect maturing evidence bases and expanding treatment options, including a recently approved immunotherapy regimen for some patients with locally advanced or metastatic disease, according to speakers at the 2019 NCCN Annual Conference, held March 21–23 in Orlando, Florida. “There are many new and emerging options for …

View Post

Immune Checkpoint Molecule Can Stop Cancer All By Itself

In In The News by Barbara Jacoby

By: News Staff From: science20.com An immune checkpoint molecule, SA-4-1BB developed for cancer immunotherapy also protects against future development of multiple types of cancer when administered by itself, shows a new study. The recombinant protein molecule SA-4-1BBL has been used to enhance the therapeutic efficacy of cancer vaccines with success in pre-clinical animal models. It accomplishes this by boosting the …

View Post

Tomorrow’s breast cancer therapy – today

In Clinical Trials by Barbara Jacoby

By: KATE ANDREWS From: chesterfieldobserver.com From ‘doing less’ to immunotherapy, clinical trials offer patients new options Women in the United States have a 1-in-8 chance of being diagnosed with breast cancer, and the disease has garnered significant attention in recent years, with football players donning pink socks and women running 5K races to raise money for research. And yet, despite …

View Post

Research to remove exclusions on immunotherapy

In Clinical Trials by Barbara Jacoby

By: Michael Hardy From: mdanderson.org People used to ask Patrick Hwu, M.D., why he decided to devote his career to melanoma, a skin cancer with high mortality rates and limited treatment options. “They would come up to me and say, ‘How can you treat advanced melanoma? Isn’t that depressing?’ And actually, it was — my clinic of advanced melanoma patients …

View Post

Researchers identify potential target for new breast cancer treatments

In In The News by Barbara Jacoby

Source: https://www.kcl.ac.uk From: news-medical.net Researchers from the School of Basic & Medical Biosciences have identified a potential target that could lead to new treatments for triple negative breast cancer. One in five patients with breast cancer are diagnosed with triple negative breast cancer, a cancer type where tumour cells don’t have receptors for oestrogen and progesterone, or the Her2 protein. …

View Post

New clinical trials at Roswell Park build on virus research for innovative immunotherapy approach

In Clinical Trials by Barbara Jacoby

By: Katie Alexander From: www.wivb.com The Roswell Park Comprehensive Cancer Center is once again on the cutting-edge of research to find new cures, and Western New Yorkers could play a big role as clinical trials open for an innovative new approach to immunotherapy. Over the decades, there has been a lot of progress for certain types of cancers with immunotherapies, …

View Post

Birmingham-Based Southern Research Introduces Transgenic Mouse Model in Support of Immuno-Oncology Therapeutic Development

In In The News by Barbara Jacoby

Southern Research – the Birmingham-based research organization specializing in drug discovery, drug development, engineering, energy and the environment– has announced the Transgenic Mouse Human PD-1/L1 Model, its newest service offering in support of immuno-oncology (IO) therapeutic development. This model could help speed the development of new cancer therapies by targeting a key checkpoint inhibitor of medicines already on the market that activate …